Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
NV

OTC · NVZMY

Novozymes A/S

Basic Materials · Chemicals - Specialty

$65.26

Up+$0.97 (+1.51%)

Updated Oct 12, 2026, 7:52 AM

SID Score

4.9/10

Composite research score

Smart Money

46/100

Neutral

Market cap
28.82B
P/E ratio
115.06
Dividend yield
1.48%
52-week range
— – —
Volume
3.56K
Avg. volume
36.05K

Price performance · NVZMY

NVZMY price history

1M range · 0 trading sessions · Daily adjusted prices

NVZMY does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest NVZMY news

The latest Smart Investors Daily articles mentioning NVZMY.

Stock researchCompany · Overview

NVZMY research

Overview

Company profile and research snapshot.

Company profile

NOVONESIS B UNSP/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
NVZMY recent ratings
DateFirmRatingTarget
Sep 23, 2026JYSKE BANKBuy—
Sep 23, 2026ROTHSCHILD & CO REDBURNBuy—
Sep 21, 2026BERENBERGBuy—
Sep 3, 2026BAADER EUROPE / ALPHAVALUEBuy—
Sep 1, 2026JEFFERIESBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 1, 2026

Novonesis completes acquisition of MicroBioGen, strengthening its yeast capabilities

Novonesis completes acquisition of MicroBioGen, strengthening its yeast capabilities The acquisition adds advanced yeast-breeding expertise with a proven track record in bioethanol and broader potential across industries. COPENHAGEN, Denmark, October 1 – Novonesis today announced the completion of its acquisition of MicroBioGen, an Australian biotechnology company with leading scientific expertise in yeast strains for industrial applications and a proven track record in bioethanol. All regulator

Yahoo · Sep 28, 2026

Novonesis celebrates major expansion of West Allis production facility, strengthening North American dairy innovation and manufacturing

Investment increases production capacity, supports booming consumer demand and reinforces Wisconsin's leadership in dairy biosolutions West Allis Ribbon Cutting Anders Lund, Chief Operating Officer and Executive Vice President at Novonesis cuts the ribbon at the West Allis ceremony. West Allis Ribbon Cutting Group photo at the Novonesis West Allis ribbon cutting on Friday, September 25 WEST ALLIS, Wis., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Novonesis, a global leader in biosolutions, announced the

Yahoo · Sep 14, 2026

Novozymes (CPSE:NSIS B) Could Be 13% Undervalued After €600 Million Patalganga Expansion

Expansion in Patalganga puts Novozymes under the spotlight Novozymes (CPSE:NSIS B) has come into focus after Novonesis announced a €600 million plan to expand its Patalganga site, with the aim of increasing biosolutions capacity for customers across high growth markets. For context, Novozymes shares last closed at DKK429.4. A 90-day share price return of 13.00% points to building momentum, even though the 1-year total shareholder return of 8.50% and the 5-year total shareholder return, which...

Yahoo · Sep 14, 2026

Initiation of Novonesis’ share buyback program

Today, Novonesis will initiate the first tranche (the “First Tranche”) of the EUR 1 billion multi-year share buyback program announced in Company Announcement No. 14, on August 19, 2026. Under the First Tranche, Novonesis will acquire B shares for an aggregate amount of up to EUR 75 million, with the First Tranche expected to end no later than December 17, 2026. Based on the closing share price on September 11, 2026, the First Tranche corresponds to around 1.3 million B shares. The shares acquir

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By